DRREDDY — Dr. Reddy's Laboratories Share News
0.000.00%
Last trade - 00:00- IN₹1.02tn
- IN₹1.01tn
- IN₹337.00bn
Brief: Dr Reddy's Clarifies News Report Dr. Reddy's Laboratories Still Awaiting Approval For A Major Near-Term Trigger
Indian pharma stocks rise as Nomura flags strong March sales
Indian's Hetero targets annual sales of 1.5 mln semaglutide pens in global rollout
India's Dr Reddy's falls after Brazil denies approval for generic semaglutide, Citi maintains 'sell'
Brief: Dr Reddy's Entered Into An Agreement For Sale Of Its Entire Shareholding In Its Unit Svaas Wellness
India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation
Brief: Corona Remedies Ltd Announces Strategic Acquisition Of Wokadine In India
UBS initiates Indian pharma coverage amid weight-loss drug opportunity
India drug regulator tightens surveillance against unauthorised weight-loss drug sales (updated)
Factbox: Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy
Brief: Dr Reddy’s Executive Says Aim To Launch Generic Semaglutide For Obesity In Next Few Months In India
Brief: Dr Reddy's Launches India's First DCGI-Approved Semaglutide Injection Obeda For Type 2 Diabetes
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
Brief: Dr Reddy's Gets Tax Penalty Of 21.9 Mln Rupees For FY2019-2020
India's Zydus, Lupin sign deal to co‑market Semaglutide injections
Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis
Indian shares rise as crude slips on Trump's Iran war comments
Indian drugmaker Dr Reddy's up after court ruling paves way for semaglutide exports
Factbox: Global drugmakers rush to boost US presence as tariff threat looms